2025 Annual General Manager's Work Report
In 2025, the management team, under the leadership of the Board of Directors, strictly adhered to the requirements of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, and the Company’s Articles of Association. They faithfully and diligently fulfilled their responsibilities, implemented the resolutions of the shareholders' meeting and the Board of Directors, and completed various tasks for the year 2025. On behalf of the management team, I hereby report to the Board of Directors on the work situation for 2025 as follows:
1. Overview of Operations
In 2025, facing a complex and changing pharmaceutical industry environment, intensified market competition, and fluctuations in raw material prices, the company adhered to a development strategy based on active pharmaceutical ingredients (APIs), with formulations as a growth point and CDMO as a new driving force. The company steadily advanced research and development, production, sales, and international compliance construction, maintaining stable overall operations, optimizing the core business structure, and achieving phased results in technological innovation and capacity construction. In 2025, the company achieved operating revenue of ¥453,306,981.13, a decrease of 1.67% compared to the same period last year; the net profit attributable to shareholders of the listed company was ¥34,910,598.79, a decrease of 61.87% compared to the same period last year. The performance fluctuations were mainly influenced by changes in market supply and demand structure, product price adjustments, and continuous increases in R&D and technological transformation investments. The company remains committed to a long-term development philosophy, continuously strengthening its core competencies in R&D, capacity, and compliance to lay a solid foundation for high-quality development in the next phase.
2. Core Business Development
The company focuses on the research and production of chemical APIs (including intermediates) and the full industry chain layout of formulations and CDMO services, forming a business system centered on non-steroidal anti-inflammatory APIs, with cardiovascular, anti-tumor, and anticholinergic specialty APIs in synergy, and self-produced APIs supporting formulations. Relying on a comprehensive R&D, production, quality, and EHS management system, the company provides full-cycle CDMO services to customers.
(1) API and Intermediate Business
The company continues to consolidate its market advantages in core products, with the API product matrix continuously improving. Non-steroidal anti-inflammatory ibuprofen and dexibuprofen maintain industry-leading positions; cardiovascular drugs such as torasemide and milrinone, anti-tumor drugs such as abiraterone acetate, fludarabine phosphate, granisetron hydrochloride, and clofarabine, and anticholinergic drugs such as atropine sulfate and scopolamine sulfate are stably supplied, with product quality and supply capacity highly recognized by domestic and international customers.